In Section I, intra- or post-procedure, specifically lead dislodgement, in post-procedure events, and Section J, discharge, specifically discharge medications, will be discussed. Indicate the location of the lead in which the dislodgement occurred between the completion of the procedure until the next procedure or discharge. The new lead locations will allow for the capture of dislodgements in a variety of locations. LV via the CVS was changed to LV-epicardial coronary venous system. Please review the training presentation regarding lead assessment for an in-depth discussion of the new lead locations. When there is more than one lead identified as dislodged in an episode of care, code the first lead identified as dislodged. The medications in Sequence 10200 have been reordered and are now consistent with the data collection form. All coding responses remain the same. Angiotensin receptor naprilicin inhibitor, renin inhibitor, and selective sinus node LF channel inhibitor has been added to the selections, which will be discussed more thoroughly in the next slides. Indicate if an angiotensin receptor naprilicin inhibitor, a renin inhibitor, or a selective sinus node LF channel inhibitor was prescribed, not prescribed, or was not prescribed due to either a medical or patient reason based on the value at discharge. Please take this opportunity to cross out or are receiving hospice care from Sequence 10200 and 10205. Angiotensin receptor naprilicin inhibitor, or more commonly called ARNI, is a combination drug that contains both an angiotensin receptor blocker, or ARB, and a naprilicin inhibitor. ARBs inhibit the activation of angiotensin II receptors, which causes vasodilation, a reduction in aldosterone production, and reduced vasopressin release, which results in a reduction of blood pressure. Naprilicin inhibition causes an increase in levels of natriuretic peptides, which is important in maintaining fluid and sodium balance, through natriuresis, diuresis, and vasodilation, which reduces blood pressure and assists in heart failure. Entrusto is one example of an angiotensin receptor naprilicin inhibitor. Renin inhibitors are a new class of drugs of which alaskarin is the only one so far licensed for the treatment of hypertension. It blocks the activity of renin and causes vasodilation by blocking the conversion of angiotensinogen to angiotensin I, which in turn reduces the formation of angiotensin II, which is a potent vasoconstrictor. Select sinus node inhibitors are a new class of drugs that target a specific area of the heart, the sinoatrial pacemaker. The first of these drugs is ivabradine, which lowers the heart rate and helps the left ventricle contract more efficiently.

patient evaluation

non-invasive testing

ischemia assessment

cardiac CTA

Coronary Artery Disease

lead dislodgement

discharge medications

angiotensin receptor naprilicin inhibitor

renin inhibitor

selective sinus node LF channel inhibitor